1. Show article details.

    Factbox: Global efforts to develop vaccines, drugs to fight the coronavirus

    Reuters – 4:38 PM ET 02/19/2020

    Researchers and drug companies are scrambling to develop vaccines and treatments to fight the new coronavirus that emerged in central China in December and has spread to more than two dozen countries, killing more than 2,000 people. There are no proven treatments for the virus and experts say it could take a year or more to have a vaccine ready. VACCINES.

  2. Show article details.

    What Apple, Walmart and other U.S. companies are saying about the coronavirus outbreak

    MarketWatch – 1:21 PM ET 02/19/2020

    By Ciara Linnane, MarketWatch, Jaimy Lee. Coronavirus is becoming a dominant theme in earnings releases and on companies' conference calls as investors seek to gauge its impact on corporate results. COVID-19, the disease caused by the new coronavirus that was first identified late last year in Wuhan, China, is becoming a dominant theme in the earnings releases and conference calls of S&P 500 companies as investors press for answers on how it will impact their financials.

  3. Show article details.

    BRIEF-Gilead Appoints Michael Quigley To Lead Research Biology Group

    Reuters – 8:35 AM ET 02/19/2020

    Gilead Sciences Inc (GILD): * GILEAD APPOINTS MICHAEL QUIGLEY TO LEAD RESEARCH BIOLOGY GROUP AND NAMES LINDA HIGGINS AS HEAD OF COMPANY’S EXTERNAL INNOVATION CENTER. * Gilead Sciences Inc (GILD) - QUIGLEY JOINS GILEAD FROM BRISTOL-MYERS SQUIBB Source text for Eikon: Further company coverage:

  4. Show article details.

    Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company’s External Innovation Center

    Business Wire – 8:30 AM ET 02/19/2020

    Gilead Sciences, Inc. (GILD) announced today that Michael Quigley, PhD has joined the company as Senior Vice President, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology.

  5. Show article details.

    Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020

    Business Wire – 8:00 PM ET 02/18/2020

    Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (GILD) today announced that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2 at 12:00 p.m. Eastern Time.

  6. Show article details.

    Sanofi to Work on Coronavirus Vaccine

    DJ Business News – 1:07 PM ET 02/18/2020

    Drug giant Sanofi SA (SNYNF) has entered the race to develop a vaccine against the new coronavirus, joining a handful of big and small drug makers, and teams of university researchers, looking for a way to prevent its spread. Sanofi (SNY) said it would revive research into a vaccine against severe acute respiratory syndrome, or SARS, an illness caused by a related coronavirus. That work, responding to an outbreak in the early 2000 s, was carried out by a small company that Sanofi (SNY) later acquired.

  7. Show article details.

    Gilead's Coronavirus Drug Trial Slowed Due to Lack of Eligible Recruits

    DJ Business News – 12:41 AM ET 02/18/2020

    BEIJING--Clinical trials being conducted in Wuhan to test Gilead Sciences Inc.' s antiviral drug, a promising remedy for the new coronavirus, are going more slowly than hoped for as the drugmaker struggles to recruit qualified patients, underscoring the challenges in quickly developing drugs during outbreaks. The trials, aimed at testing more than 700 patients infected with the Wuhan coronavirus, have succeeded in recruiting fewer than 200 people after 10 days.

  8. Show article details.

    Gilead drug prevents type of coronavirus in monkeys; raises hope for China trials

    Reuters – 5:35 PM ET 02/13/2020

    An experimental Gilead Sciences (GILD) antiviral drug prevented disease and reduced the severity of symptoms in monkeys infected with Middle East Respiratory Syndrome, an infection closely related to the fast-spreading coronavirus that originated in China, a study published on Thursday found.

  9. Show article details.

    Results from Chinese drug trials for coronavirus due in weeks -expert

    Reuters – 4:30 PM ET 02/12/2020

    Chinese scientists are testing two antiviral drugs against the new coronavirus and preliminary clinical trial results are weeks away, the co-chair of a World Health Organization meeting said on Wednesday.

  10. Show article details.

    Correction to Report About Gilead Sciences' Work on a Coronavirus Drug

    DJ Business News – 1:27 PM ET 02/12/2020

    Gilead Sciences' (GILD) chief medical officer, Merdad Parsey, said a patient's recovery after taking the company's drug could be an anecdote. "Gilead Sciences Scrambles to Supply Experimental Coronavirus Drug" at 11:07 a.m. ET, incorrectly quoted him saying it could be an antidote in the fourth paragraph. (END) Dow Jones Newswires 02-12-20 1327 ET Copyright (c) 2020 Dow Jones& Company, Inc..

  11. Show article details.

    Gilead Sciences Scrambles to Supply Experimental Coronavirus Drug

    DJ Business News – 11:06 AM ET 02/12/2020

    A team of a dozen executives at drugmaker Gilead Sciences Inc. (GILD) meets daily to discuss the coronavirus epidemic in China and the company's cross-continental scramble to develop the first drug for the new disease. If the company's drug succeeds in studies in China, it could become the first treatment proven to work against a respiratory virus that has killed more than 1,000 people and infected some 42,600 in fewer than three months. There are some positive albeit preliminary...

  12. Show article details.

    BRIEF-Gilead Sciences Reports 9.99% Passive Stake In Sierra Oncology

    Reuters – 5:43 PM ET 02/10/2020

    Gilead Sciences Inc (GILD): * GILEAD SCIENCES INC REPORTS 9.99% PASSIVE STAKE IN SIERRA ONCOLOGY AS OF JAN 31 - SEC FILING Source: Further company coverage:

  13. Show article details.

    BRIEF-U.S. FDA Grants Priority Review For Kite's KTE-X19 Biologics License Application

    Reuters – 9:27 AM ET 02/10/2020

    Gilead Sciences Inc (GILD): * U.S. FDA GRANTS PRIORITY REVIEW FOR KITE'S KTE-X19 BIOLOGICS LICENSE APPLICATION IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA. * Gilead Sciences Inc (GILD) - PDUFA OR TARGET ACTION DATE IS AUGUST 10, 2020 Source text for Eikon: Further company coverage:

  14. Show article details.

    U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma

    Business Wire – 8:30 AM ET 02/10/2020

    -- If Approved, Kite Could be First Company with Multiple Commercialized CAR T Therapies -- Kite, a Gilead Company, today announced that the U.S. Food and Drug Administration has accepted the Biologics License Application and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractor...

  15. Show article details.

    BRIEF-Porton Pharma Solutions Receives Gilead Science's Confirmation Letter Of Pharmaceutical Intermediate Order For Remdesivir

    Reuters – 5:34 AM ET 02/07/2020

    Porton Pharma Solutions Ltd: * SAYS IT HAS RECEIVED FROM GILEAD SCIENCE CONFIRMATION LETTER FOR PHARMACEUTICAL INTERMEDIATE ORDER FOR REMDESIVIR Source text in Chinese: shorturl.at/btFHU Further company coverage:

  16. Show article details.

    Drugmakers see long road ahead in coronavirus vaccine race

    Reuters – 9:14 PM ET 02/05/2020

    - Drugmakers racing to find a vaccine or effective treatment for the deadly new coronavirus in China cautioned that they have a long way to go. That runs counter to reports of a supposed "breakthrough" that on Wednesday boosted financial markets and spurred optimism not necessarily backed by reality.

  17. Show article details.

    FOCUS-Drugmakers see long road ahead in coronavirus vaccine race

    Reuters – 3:19 PM ET 02/05/2020

    Drugmakers racing to find a vaccine or effective treatment for the deadly new coronavirus in China cautioned that they have a long way to go. That runs counter to reports of a supposed "breakthrough" that on Wednesday boosted financial markets and spurred optimism not necessarily backed by reality.

  18. Gilead downgraded to outperform from strong buy at Raymond James

    MarketWatch – 8:08 AM ET 02/05/2020
  19. Show article details.

    WHO: "no known effective" treatments for new coronavirus

    Reuters – 7:42 AM ET 02/05/2020

    The World Health Organization played down media reports on Wednesday of "breakthrough" drugs being discovered to treat people infected with the new coronavirus, which is causing an epidemic in China and has spread to at least 20 other countries.

  20. Show article details.

    China lab seeks patent on use of Gilead's coronavirus treatment

    Reuters – 2:10 AM ET 02/05/2020

    A state-run Chinese research institute has applied for a patent on the use of Gilead Sciences' (GILD) experimental U.S. antiviral drug, which scientists think could provide treatment for the coronavirus that has killed hundreds and infected thousands.

Page:

Today's and Upcoming Events

  • Apr
    30

    GILD to announce Q1 earnings (Unconfirmed)

  • Mar
    12

    GILD ex-Dividend for $0.68 on 03/12/2020

    • Announce Date: 02/04/2020
    • Record Date: 03/13/2020
    • Pay Date: 03/30/2020

Past Events (last 90 days)

  • Feb
    04

    GILD announced Q4 earnings.

  • Dec
    12

    GILD ex-Dividend for $0.63 on 12/12/2019

    • Announce Date: 10/23/2019
    • Record Date: 12/13/2019
    • Pay Date: 12/30/2019
Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.